Mifepristone in Children With Refractory Cushing's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01925092|
Recruitment Status : Withdrawn (Lack of enrollment)
First Posted : August 19, 2013
Last Update Posted : August 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cushing's Disease||Drug: mifepristone||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||December 2016|
Daily doses of mifepristone over 84 days.
Other Name: Korlym
- Adverse events [ Time Frame: collected during the12 week study and 4 week follow-up period; up to 16 weeks total. ]Patients who have received at least 1 dose of mifepristone will be included in the safety evaluations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925092
|United States, Maryland|
|National Institute of Child Health and Human Development (NICHD)|
|Bethesda, Maryland, United States, 20892-1103|